Ox-LDL Particles: Modified Components, Cellular Uptake, Biological roles and clinical assessments

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 11, Issue 2, 2011, Pages 119-128

  Najafi, Mohammad ^a   Roustazadeh, Abazar ^a   Alipoor, Behnam ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blocks; Cardiovascular disease; Components; Ox LDL; Scavenger receptors

Indexed keywords

4 HYDROXYNONENAL; ALDEHYDE; CD36 ANTIGEN; CERAMIDE; FC RECEPTOR; HYPOCHLORITE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; MALONALDEHYDE; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; OXYSTEROL; PEROXYNITRITE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A2; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR B; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE; STAT1 PROTEIN; STAT3 PROTEIN; SUPEROXIDE; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR HP1; UNCLASSIFIED DRUG; UNINDEXED DRUG; BIOLOGICAL MARKER;

ACETYLATION; ACUTE CORONARY SYNDROME; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BINDING AFFINITY; BINDING SITE; BIOINFORMATICS; BLOOD CHEMISTRY; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL DEATH; CELL PROLIFERATION; CELL TRANSPORT; CLINICAL ASSESSMENT; CONSENSUS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; GENE SEQUENCE; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INTERNALIZATION; LIPID ANALYSIS; LIPID PEROXIDATION; MACROPHAGE; MOLECULAR RECOGNITION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARTICLE SIZE; PREECLAMPSIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; SCAVENGING SYSTEM; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR SMOOTH MUSCLE; METABOLISM; OXIDATION REDUCTION REACTION;

BIOMARKERS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, LDL; OXIDATION-REDUCTION;

EID: 83455194891     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152911798346990     Document Type: Article

References (113)

1. Berliner, J.A.; Territo, M.C.; Sevanian, A.; Ramin, S.; Kim, J.A.; Bamshad, B.; Esterson, M.; Fogelman, A.M. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J. Clin. Invest., 1990, 85, 1260-1266.
2. Roy Chowdhury, S.K.; Sangle, G.V.; Xie, X.; Stelmack, G.L.; Halayko, A.J.; Shen, G.X. Effects of extensively oxidized lowdensity lipoprotein on mitochondrial function and reactive oxygen species in porcine aortic endothelial cells: Am. J. Physiol. Endocrinol. Metab., 2010, 298(1), E89-98.
3. Chávez-Sánchez, L.; Chávez-Rueda, K.; Legorreta-Haquet, M.V.; Zenteno, E.; Ledesma-Soto, Y.; Montoya-Díaz, E.; Tesoro-Cruz, E.; Madrid-Miller, A.; Blanco-Favela, F. Lipids Health Dis., 2010, 14, 9-117.
4. Thai, S.F.; Lewis, J.G.; Williams, R.B.; Johnson, S.P.; Adams, D.O. Effects of oxidized LDL on mononuclear phagocytes: inhibition of induction of four inflammatory cytokine gene RNAs, release of NO, and cytolysis of tumor cells. J. Leukoc. Biol., 1995, 57(3), 427-33.
5. Fukuchi, M.; Watanabe, J.; Kumagai, K.; Baba, S.; Shinozaki, T.; Miura, M.; Kagaya, Y.; Shirato, K. Normal and oxidized low density lipoproteins accumulate deep in physiologically thickened intima of human coronary arteries. Lab. Invest., 2002, 82(10), 1437-47.
6. Boullier, A.; Li, Y.; Quehenberger, O.; Palinski, W.; Tabas, I.; Witztum, J.L.; Miller, Y.I. Minimally oxidized LDL offsets the apoptotic effects of extensively oxidized LDL and free cholesterol in macrophages. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 1169-1176.
7. Gaubatz, J.W.; Gillard, B.K.; Massey, J.B.; Hoogeveen, R.C.; Huang, M.; Lloyd, E.E.; Raya, J.L.; Yang, C.Y.; Pownall, H.J. Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A2. J. Lipid Res., 2007, 48, 348-357.
8. Tietge, U.J.F.; Pratico, D.; Ding, T.; Funk, C.D.; Hildebrand, R.B.; Van Berkel, T.; Van Eck, M. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. J. Lipid Res., 2005, 46, 1604-1614.
9. Singh, D.K.; Subbaiah, P.V. Modulation of the activity and arachidonic acid selectivity of group X secretory phospholipase A 2 by sphingolipids. J. Lipid Res., 2007, 48, 683-692.
10. Subbanagounder, G.; Watson, A.D.; Berliner, J.A. Bioactive products of phospholipid oxidation: Isolation, identification, measurement and activities. Free Radical. Biol. Med., 2000, 28, 1751-1761.
11. Silva, A.R.; de Assis, E.F.; Caiado, L.F.; Marathe, G.K.; Bozza, M.T.; McIntyre, T.M.; Zimmerman, G.A.; Prescott, S.M.; Bozza, P.T.; Castro-Faria-Neto, H.C. J. Immunol., 2002, 168(8), 4112-20.
12. Zemski Berry, K.A.; Murphy, R.C. Free radical oxidation of plasmalogen glycerophosphocholine containing esterified docosahexaenoic acid: structure determination by mass spectrometry. Antioxid. Redox. Signal, 2005, 7(1-2), 157-69.
13. Xie, Z.; Barski, O.A.; Cai, J.; Bhatnagar, A.; Tipparaju, S.M. Catalytic reduction of carbonyl groups in oxidized PAPC by Kvβ2 (AKR6). Chem. Biol. Interact, 2011, 191(1-3), 255-60.
14. Altmann, R.; Hausmann, M.; Spöttl, T,; Gruber, M.; Bull, A.W.; Menzel, K.; Vogl, D.; Herfarth, H.; Schölmerich, J.; Falk, W.; Rogler, G. 13-Oxo-ODE is an endogenous ligand for PPARgamma in human colonic epithelial cells. Biochem. Pharmacol., 2007, 74(4), 612-22.
15. Hammad, S.M.; Taha, T.A.; Nareika, A.; Johnson, K.R.; Lopes-Virella, M.F.; Obeid, L.M. Oxidized LDL immune complexes induce release of sphingosine kinase in human U937 monocytic cells. Prostaglandins Other Lipid Mediat., 2006, 79(1-2), 126-40.
16. Staprans, I.; Pan, X.M.; Rapp, J.H.; Feingold, K.R. The role of dietary oxidized cholesterol and oxidized fatty acids in the development of atherosclerosis. Mol. Nutr. Food Res, 2005, 49(11), 1075-82.
17. Leonarduzzi, G.; Chiarpotto, E.; Biasi, F.; Poli, G. 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Mol. Nutr. Food Res., 2005, 49(11), 1044-9.
18. Zamara, E.; Novo, E.; Marra, F.; Gentilini, A.; Romanelli, R.G.; Caligiuri, A.; Robino, G.; Tamagno, E.; Aragno, M.; Danni, O.; Autelli, R.; Colombatto, S.; Dianzani, M.U.; Pinzani, M.; Parola, M. 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J. Hepatol., 2004, 40(1), 60-8.
19. Domange. J.E.; Wermeling, F.; Chen, Y.; Karlsson, M.C. Scavenger receptors as regulators of natural antibody responses and B cell activation in autoimmunity. Mol. Immunol., 2011, 48(11), 1307-18.
20. Haberland, M.E.; Olch, C.L.; Folgelman, A.M. Role of lysines in mediating interaction of modified low density lipoproteins with the scavenger receptor of human monocyte macrophages. J. Biol. Chem., 1984, 259, 11305-11311.
21. Babiy, A.V.; Gebicki, J.M. Decomposition of lipid hydroperoxides enhances the uptake of low density lipoprotein by macrophages. Acta Biochim. Pol., 1999, 46, 31-42.
22. Linton, M.F.; Fazio, S. Class A scavenger receptors, macrophages, and atherosclerosis. Curr. Opin. Lipidol., 2001, 12(5), 489-95.
23. Bowdish, D.M.; Sakamoto, K.; Kim, M.J.; Kroos, M.; Mukhopadhyay, S.; Leifer, C.A.; Tryggvason, K.; Gordon, S.; Russell, D.G. MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis. PLoS Pathog., 2009, 5(6), e1000474.
24. Plüddemann, A.; Neyen, C.; Gordon, S. Macrophage scavenger receptors and host-derived ligands. Method, 2007, 43, 207-217.
25. Silverstein, R.L.; Li, W.; Park, Y.M.; Rahaman, S.O. Mechanisms of cell signaling by the scavenger receptor CD36: implications in atherosclerosis and thrombosis. Trans. Am. Clin. Climatol. Assoc., 2010, 121, 206-20.
26. Podrez, E.A.; Febbraio, M.; Sheibani, N.; Schmitt, D.; Silverstein, R.L.; Hajjar, D.P.; Cohen, P.A.; Frazier, W.A.; Hoff HF, Hazen, S.L. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J. Clin. Invest., 2000, 105, 1095-1108.
27. Irena, L.; Suncica, V.; Papasani, V. Subbaiah. Antioxidants & Redox Signaling. 2010, 13(1), 39-75.
28. Kunjathoor, V.V.; Febbraio, M.; Podrez, E.A.; Moore, K.J.; Andersson, L.; Koehn, S.; Rhee, J.S.; Silverstein, R.; Hoff, H.F.; Freeman, M.W. Scavenger receptors Class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem., 2002, 277, 49982-49988.
29. Ji, A.; Meyer, J.M.; Cai, L.; Akinmusire, A.; de Beer, M.C.; Webb, N.R.; van der, Westhuyzen, D.R. Scavenger receptor SR-BI in macrophage lipid metabolism. Atherosclerosis. 2011.
30. Pirillo, A.; Reduzzi, A.; Ferri, N.; Kuhn, H.; Corsini, A.; Catapano, A.L. Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. Atherosclerosis, 2011, 214(2), 331-7.
31. Murphy, J.E.; Tacon, D.; Tedbury, P.R.; Hadden, J.M.; Knowling, S.; Sawamura, T.; Peckham, M.; Phillips, S.E.; Walker, J.H. Ponnambalam S LOX-1 scavenger receptor mediates calciumdependent recognition of phosphatidylserine and apoptotic cells. Biochem. J., 2006, 1, 393(Pt 1), 107-15.
32. Shaw, P.X.; Goodyear, C.S.; Chang, M.K.; Witztum, J.L.; Silverman, G.J. The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cells. J. Immunol., 2003, 15, 6151-6157.
33. van der Meer, I.M.; Witteman, J.C.; Hofman, A.; Kluft, C.; de Maat, M.P. Genetic variation in Fcgamma receptor IIa protects against advanced peripheral atherosclerosis. Thromb. Haemost., 2004, 92(6), 1273-6.
34. Horiuchi, S.; Sakamoto, Y.; Sakai, M. Scavenger receptors for oxidized and glycated proteins. Amino Acids, 2003, 25(3-4), 283-92.
35. Ashraf, M.Z.; Gupta, N. Scavenger receptors: Implications in atherothrombotic disorders. Int. J. Biochem. Cell Biol., 2011, 43(5), 697-700.
36. Curtiss, L.K.; Tobias, P.S.E. merging role of Toll-like receptors in atherosclerosis. J. Lipid Res., 2009, 50 Suppl, S340-5.
37. Wiesner, P.; Choi, S.H.; Almazan, F.; Benner, C.; Huang, W.; Diehl, C.J.; Gonen, A.; Butler, S.; Witztum, J.L.; Glass, C.K.; Miller, Y.I. Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor kappa B and activator protein-1: possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia. Circ. Res, 2010, 107(1), 56-65.
38. Mazière, C.; Mazière, J.C. Activation of transcription factors and gene expression by oxidized low-density lipoprotein. Free Radic. Biol. Med., 2009, 46(2), 127-37.
39. D'Archivio, M.; Scazzocchio, B.; Filesi, C.; Varì, R.; Maggiorella, M.T.; Sernicola, L.; Santangelo, C.; Giovannini C.; Masella, R. Oxidised LDL up-regulate CD36 expression by the Nrf2 pathway in 3T3-L1 preadipocytes. FEBS Lett., 2008, 582(15), 2291-8.
40. Lei, X.; Fujiwara, Y.; Chang, C.C.; Chang, T.Y.; Takeya, M.; Sakashita, N.J. Association of ACAT1-positive vesicles with late endosomes/ lysosomes in cholesterol-rich human macrophages. Atheroscler. Thromb., 2010, 17(7), 740-50.
41. Jerome, W.G.; Yancey, P.G. The role of microscopy in understanding atherosclerotic lysosomal lipid metabolism. Microsc. Microanal., 2003, 9(1), 54-67.
42. Wu, B.J.; Kathir, K.; Witting, P.K.; Beck, K.; Choy, K.; Li, C.; Croft, K.D.; Mori, T.A.; Tanous, D.; Adams, M.R.; Lau, A.K.; Stocker, R. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J. Exp. Med., 2006, 203, 1117-1127.
43. Heinecke, J.W. Lipoprotein oxidation in cardiovascular disease: Chief culprit or innocent bystander? J. Exp. Med., 2006, 203, 813-816.
44. Galle, J.; Schneider, R.; Heinloth, A.; Wanner, C.; Galle, P.R.; Conzelmann, E.; Dimmeler, S.; Heermeier, K. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int., 1999, 55, 1450-61.
45. Galle, J.; Hansen-Hagge, T.; Wanner, C.; Seibold, S. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis, 2006, 185, 219-26.
46. Barlic, J.; Zhang, Y.; Foley, J.F.; Murphy, P.M. Oxidized lipiddriven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor γ-dependent pathway. Circulation, 2006, 114, 807-19.
47. Mehta, J.L.; Li, D.Y. Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells. Biochem. Biophys. Res. Commun., 1998, 248, 511-514.
48. Tanner, F.C.; Noll, G.; Boulanger, C.M.; Luscher, T.F. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. Circulation, 1991, 83, 2012-2020.
49. Ananyeva, N.M.; Tjurmin, A.V.; Berliner, J.A.; Chisolm, G.M.; Liau, G.; Winkles, J.A.; Haudenschild, C.C. Oxidized LDL mediates the release of fibroblast growth factor-1. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 445-453.
50. Li, D.; Mehta, J.L. Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Am. J. Physiol., 1998, 275, 568-576.
51. Kusuhara, M.; Chait, A.; Cader, A.; Berk, B.C. Oxidized LDL stimulates mitogen-activated protein kinases in smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 141-148.
52. Tanigawa, H.; Miura, S.; Zhang, B.; Uehara, Y.; Matsuo, Y.; Fujino, M.; Sawamura, T.; Saku, K. Low-density lipoprotein oxidized to various degrees activates ERK1/2 through LOX-1. Atherosclerosis, 2006, 188, 245-50.
53. Tanigawa, H.; Miura, S.; Matsuo, Y.; Fujino, M.; Sawamura, T.; Saku, K. Dominant-negative Lox-1 blocks homodimerization of wild-type Lox-1-induced cell proliferation through extracellular signal regulated kinase 1/2 activation. Hypertension, 2006, 48, 294-300.
54. Ishii, N.; Matsumura, T.; Kinoshita, H.; Motoshima, H.; Kojima, K.; Tsutsumi. A.; Kawasaki, S.; Yano, M.; Senokuchi, T.; Asano, T.; Nishikawa, T.; Araki, E. Activation of AMP-activated Protein Kinase Suppresses Oxidized Low-density Lipoprotein-induced Macrophage Proliferation. J. Biol. Chem., 2009, 284, 34561-34569.
55. Ishigaki, Y.; Oka, Y.; Katagiri, H. Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr. Opin. Lipidol., 2009, 20, 363-369.
56. Sherer, Y.; Cerinic, M.M.; Bartoli, F.; Blagojevic, J.; Conforti, M.L.; Gilburd, B.; Ehrenfeld, M.; Shoenfeld, Y. Early atherosclerosis and autoantibodies to heat-shock proteins and oxidized LDL in systemic sclerosis. Ann. NY Acad. Sci., 2007, 1108, 259-67.
57. McDowell, A.; Young, I.S.; Wisdom, G.B. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease. J. Pharm. Pharmacol., 2002, 54, 1651-7.
58. Matsumoto, T.; Takashima, H.; Ohira, N.; Tarutani, Y.; Yasuda, Y.; Yamane, T.; Matsuo, S.; Horie, M. Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin. J. Am. Coll. Cardiol., 2004, 44, 451-457.
59. Nishi, K.; Itabe, H.; Uno, M.; Kitazato, K.T.; Horiguchi, H.; Shinno, K,; Nagahiro, S. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 1649-1654.
60. Toshima, S.; Hasegawa, A.; Kurabayashi, M.; Itabe, H.; Takano, T.; Sugano, J.; Shimamura, K.; Kimura, J.; Michishita, I.; Suzuki, T.; Nagai, R. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2243-2247.
61. Holvoet, P.; Mertens, A.; Verhamme, P.; Bogaerts, K.; Beyens, G.; Verhaeghe, R.; Collen, D.; Muls, E.; Van de Werf, F. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 844-848.
62. Tsimikas, S.; Brilakis, E.S.; Miller, E.R.; McConnell, J.P.; Lennon, R.J.; Kornman, K.S.; Witztum, J.L.; Berger, P.B. Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease. N. Engl. J. Med., 2005, 353, 46-57.
63. Tsimikas, S.; Witztum, J.L. Measuring circulating oxidized lowdensity lipoprotein to evaluate coronary risk. Circulation, 2001, 103, 1930-2.
64. Ehara, S.; Ueda, M.; Naruko, T.; Haze, K.; Itoh, A.; Otsuka, M.; Komatsu, R.; Matsuo, T.; Itabe, H.; Takano, T.; Tsukamoto, Y.; Yoshiyama, M.; Takeuchi, K.; Yoshikawa, J.; Becker, A.E. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation, 2001, 103, 1955-60.
65. Holvoet, P.; Collen, D.; Van de Werf, F. Malondialdehydemodified LDL as a marker of acute coronary syndromes. JAMA, 1999, 281, 1718-21.
66. Tsimikas, S.; Bergmark, C.; Beyer, R.W.; Patel, R.; Pattison, J.; Miller, E.; Juliano, J.; Witztum, J.L. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J. Am. Coll. Cardiol., 2003, 41, 360-70.
67. Tsimikas, S.; Lau, H.K.; Han, K.R.; Shortal, B.; Miller, E.R.; Segev, A.; Curtiss, L.K.; Witztum, J.L.; Strauss, B.H. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation, 2004, 109, 3164-70.
68. Tsimikas, S.; Witztum, J.L.; Miller, E.R.; Sasiela, W.J.; Szarek, M.; Olsson, A.G.; Schwartz, G.G. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation, 2004, 110, 1406-12.
69. Huang, H.; Mai, W.; Liu, D.; Hao, Y.; Tao, J.; Dong, Y. The oxidation ratio of LDL: a predictor for coronary artery disease. Dis. Markers, 2008, 24, 341-9.
70. Meisinger, C.; Baumert, J.; Khuseyinova, N.; Loewel, H.; Koenig, W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middleaged men from the general population. Circulation, 2005, 112, 651-7.
71. Braun, S.; Ndrepepa, G.; von Beckerath, N.; Mehilli, J.; Gorchakova, O.; Vogt, W,; Schömig, A.; Kastrati, A. Lack of association between circulating levels of plasma oxidized lowdensity lipoproteins and clinical outcome after coronary stenting. Am. Heart J., 2005, 150, 550-6.
72. Najafi, M.; Gohari, L.H.; Firoozrai, M. Paraoxonase 1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries. Thromb. Res., 2009, 123(3), 503-10.
73. Thygesen, K.; Alpert, J.S.; White, H.D.; Jaffe, A.S.; Apple, F.S.; Galvani, M. Universal definition of myocardial infarction. Circulation, 2007, 116, 2634-53.
74. Holvoet, P.; Harris, T.B.; Tracy, R.P.; Verhamme, P.; Newman, A.B.; Rubin, S.M.; Simonsick. E.M.; Colbert, L.H.; Kritchevsky, S.B. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging and Body Composition study. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 1444-1448.
75. Weinbrenner, T.; Cladellas, M.; Isabel, C.M.; Fitó, M.; Tomás, M.; Sentí, M.; Bruguera, J.; Marrugat, J. High oxidative stress in patients with stable coronary heart disease. Atherosclerosis, 2003, 168, 99-106.
76. Wu, T.; Willett. W.C.; Rifai N.; Shai I.; Manson. J.E.; Rimm, E.B. Is Plasma Oxidized Low-Density Lipoprotein, Measured With the Widely Used Antibody 4E6, an Independent Predictor of Coronary Heart Disease Among U.S. Men and Women?: J. Am. Coll. Cardiol., 2006, 48, 973-9.
77. Falk, E.; Shah, P.K.; Fuster. V. Coronary plaque disruption. Circulation, 1995, 92, 657-671.
78. Virmani, R.; Kolodgie, F.D.; Burke, A.P.; Farb, A.; Schwartz, S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 1262-1275.
79. Cho, KH.; Shin, D.G.; Baek, S.H.; Kim, J.R. Myocardial infarction patients show altered lipoprotein properties and functions when compared with stable angina pectoris patients. Exp. Mol. Med., 2009, 41, 67-76.
80. Huang, H; Mai, W; Liu, D; Hao, Y; Tao, J; Dong, Y. The oxidation ratio of LDL: a predictor for coronary artery disease. Dis. Markers., 2008, 24, 341-9.
81. Schwenke, D.C.; Zilversmit, D.B. The arterial barrier to lipoprotein influx in the hypercholesterolemic rabbit: I. Studies during the first two days after mild aortic injury: Atherosclerosis, 1989, 77, 91-103.
82. Schwenke, D.C.; Carew, T.E. Initiation of atherosclerotic lesion in cholesterol-fed rabbits: II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis, 1989, 9, 908-18.
83. Seo, H.; Oh, H.; Park, H.; Park, M.; Jang, Y.; Lee, M. Contribution of Dietary Intakes of Antioxidants to Homocysteine-Induced Low Density Lipoprotein (LDL) Oxidation in Atherosclerotic Patients. Yonsei Med. J., 2010, 51, 526-33.
84. Jakubowski, H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J. Nutr., 2000, 130, 377S-81.
85. Dardik, R.; Varon, D.; Tamarin, I.; Zivelin, A.; Salomon, O.; Shenkman, B.; Savion, N. Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Thromb. Haemost., 2000, 83, 338-44.
86. Vadachkoria, S.; Sanchez, S.E.; Qiu, C.; Muy-Rivera, M.; Malinow, M.R.; Williams, M.A. Hyperhomocyst(e)inemia and elevated soluble vascular cell adhesion molecule-1 concentrations are associated with an increased risk of preeclampsia. Gynecol. Obstet. Invest., 2004, 58, 133-9.
87. Erl, W.; Weber, P.C.; Weber, C. Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands. Atherosclerosis, 1998, 136, 297-303.
88. Maggi, E.; Chiesa, R.; Melissano, G.; Castellano, R.; Astore, D.; Grossi, A.; Finardi, G.; Bellomo, G. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler. Thromb., 1994, 14, 1892-9.
89. Bui, M.N.; Sack, M.N.; Moutsatsos, G.; Lu, D.Y.; Katz, P.; McCown, R.; Breall, J.A.; Rackley, C.E. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am. Heart J., 1996, 131, 663-7.
90. George, J.; Harats, D.; Bakshi, E.; Adler, Y.; Levy, Y.; Gilburd, B.; Shoenfeld, Y. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol. Lett., 1999, 68, 263-6.
91. McNeil, HP.; Simpson, R.J.; Chesterman, C.N.; Krilis, S.A. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. USA, 1990, 87, 4120-4124.
92. Shi G.P. Immunomodulation of Vascular Diseases: Atherosclerosis and Autoimmunity. Eur. J. Vasc. Endovasc. Surg., 2010, 39, 485-494.
93. Van Berkel, T.J.; De Rijke, Y.B.; Kruijt, J.K. Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats. Recognition by various scavenger receptors on Kupffer and endothelial liver cells. J. Biol. Chem., 1991, 266, 2282-2289.
94. EL Magadmi, M.; Ahmad, Y.; Turkie, W.; Yates, A.P.; Sheikh, N.; Bernstein, R.M.; Durrington, P.N.; Laing, I.; Bruce, I.N. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J. Rheumatol., 2006, 33(1), 50-6.
95. Lopez, L. R; Salazar-Paramo, M.; Palafox-Sanchez, C.; Hurley, B.L.; Matsuura, E.; Garcia-De La, I. Oxidized low-density lipoprotein and β2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus, 2006, 15(2), 80-6.
96. Bassi, N.; Zampieri, S.; Ghirardello, A.; Tonon, M.; Zen, M.; Beggio, S.; Matsuura, E.; Doria, A. oxLDL/beta2GPI complex and anti-oxLDL/beta2GPI in SLE: prevalence and correlates. Autoimmunity, 2009, 42(4), 289-91.
97. Hayem, G.; Nicaise-Roland, P.; Palazzo, E.; Bandt, M.; Tubach, F.; Weber, M.; Meyer, O. Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus, 2001, 10(5), 346-51.
98. Locht, H.; Wiik, A. Prevalence of antibodies against oxidised LDL in a cohort of 163 patients with positive anti-phospholipid antibodies and recent thrombosis. Rheumatol. Int., 2006, 26(5), 416-21.
99. Cvetkovic, J.T.; Wållberg-Jonsson, S.; Ahmed, E.; Rantapää-Dahlqvist, S.; Lefvert, A.K. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehydemodified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology (Oxford), 2002, 41(9), 988-95.
100. Peters, M.J.; Halm, V. P,; Nurmohamed, M.T.; Damoiseaux, J.; Tervaert, J.W.; Twisk, J.W.; Dijkmans, B.A.; Voskuyl, A.E. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J. Rheumatol., 2008, 35(8), 1495-9.
101. Orem, A.; Cimşit, G.; Deǧer, O.; Orem, C.; Vanizor, B. The significance of autoantibodies against oxidatively modified lowdensity lipoprotein (LDL) in patients with psoriasis. Clin. Chim. Acta, 1999, 15, 284(1):81-8.
102. Hoogeveen, R.C.; Ballantyne, C.M.; Bang, H.; Heiss, G.; Duncan, B.B.; Folsom, A.R.; Pankow, J.S. Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Diabetologia., 2007, 50(1), 36-42.
103. El-Bassiouni, E.A.; Helmy, M.H.; El-Zoghby, S.M.; El-Nabi Kamel M.A.; Hosny, R.M. Relationship between level of circulating modified LDL and the extent of coronary artery disease in type 2 diabetic patients. Br. J. Biomed. Sci., 2007, 64(3), 109-16.
104. Rizzo, M.; Berneis, K.; Koulouris, S.; Pastromas, S.; Rini, G.B.; Sakellariou, D.; Manolis, A.S. Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?: Int. J. Clin. Pract., 2010, 64(12), 1632-42.
105. Shoji, T.; Kimoto, E.; Shinohara, K.; Emoto, M.; Ishimura, E.; Miki, T.; Tsujimoto, Y.; Tabata, T.; Nishizawa, Y. The association of antibodies against oxidized low-density lipoprotein with atherosclerosis in hemodialysis patients. Kidney Int. Suppl., 2003, (84), S128-30.
106. Uotila, J.; Solakivi, T.; Jaakkola, O.; Tuimala, R.; Lehtimäki, T. Antibodies against copper-oxidised and malondialdehyde-modified low density lipoproteins in pre-eclamptic pregnancies. Br. J. Obstet. Gynaecol., 1998, 105(10), 1113-7.
107. Raijmakers, MT.; van Tits, B.J.; Hak-Lemmers, H.L.; Roes, E.M.; Steegers, E.A.; Peters, W.H. Low plasma levels of oxidized low density lipoprotein in preeclampsia. Acta Obstet. Gynecol. Scand., 2004, 83(12), 1173-7.
108. Djuro, M.; Svetozar, D.; Dimitrios. P.; Nikolaos, S.; Biljana, G.; Milan, P.; David, R.; Anargyros, K.; Jelica, B.; Nataša, M. Oxidised low-density lipoprotein concentration-early marker of an altered lipid metabolism in young women with PCOS. Eur. J. Endocrinol., 2006, 155, 131-136.
109. Pohjantähti-Maaroos, H.; Palomäki, A. Comparison of metabolic syndrome subjects with and without erectile dysfunction-levels of circulating oxidised LDL and arterial elasticity. Int. J. Clin. Pract., 2011, 65(3), 274-80.
110. Koji, S.; Yoshinori, I.; Kenji, W. Serum Oxidized Low-Density Lipoprotein Levels and Risk of Colorectal Cancer: A Case-Control Study Nested in the Japan Collaborative Cohort Study. Cancer Epidemiol. Biomarkers Prev., 2004, 13, 1781-1787.
111. Yan, W.; Hao, L.; Yutao, D.; Huiqing L.; Yukun, Z.; Chang, Y.; Yongchun, C.; Qing, M.; Xueqiang, F.; Yingzhi, Z.; Yanfang Y. Relationship Between Oxidized LDL Antibodies and Different Stages of Esophageal Carcinoma. Arch. Med. Res., 2008, 39(8), 760-7.
112. Ioannis, D.; Elsa, F.; Georgios, A.; Eleni, S.; Ariadni, Z.; Amalia, D.A. Oxidized LDL, serum oxidizability and serum lipid levels in patients with breast or ovarian cancer. Clin. Biochem., 2007, 40(15), 1129-34.
113. Motta, M.; Pistone, G.; Franzone, A.M.; Romeo, M.A.; Di Mauro, S.; Giugno, I.; Ruello, P.; Malaguarnera, M. Antibodies against ox-LDL serum levels in patients with hepatocellular carcinoma. Panminerva. Med., 2003, 45(1), 69-73.